From a modest start in February 2000, ClinicalTrials.gov has become a critical part of the U.S. Food and Drug Administration's (FDA) efforts to protect public health.
Making clinical trial information publicly available fulfills the FDA's commitment to research participants and also enhances public trust.
Another significant benefit is the sharing of unfavorable study results.
Before launching ClinicalTrials.gov, many (vaccine) studies went unreported in the scientific literature, leading to a biased perspective on the benefits and risks of interventions.
-
-
COVID-19 Pandemic Challenges Osteoporosis Management
-
AstraZeneca, J&J Resume U.S. COVID-19 Vaccine Trials
-
Survival From COVID-19 High in Patients With Psoriasis
-
FDA Needs More Safety Data on COVID-19 Vaccines, Experts Say
